Physicians' Academy for Cardiovascular Education

Efficacy and safety of P2Y12 inhibitors comparable between men and women

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials

Literature - Lau ES, Braunwald E, Murphy SA, et al. - J Am Coll Cardiol. 2017;69(12):1549-1559


The efficacy and safety of P2Y12 inhibitors in women is not adequately established, due to their underrepresentation in clinical studies [1,2]. There are concerns because of gender-specific differences in the pharmacodynamics and due to the fact that women are at increased risk of bleeding after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) [3-6].

In this meta-analysis of 7 phase III or IV RCTs, the gender-specific efficacy and safety of P2Y12 inhibitors prasugrel, ticagrelor and cangrelor were evaluated in patients with stable and unstable coronary artery disease (CAD). For this, end points with P2Y12 inhibitors were compared with these of clopidogrel (6 studies) or placebo (1 study).

Main results


The efficacy and safety of P2Y12 inhibitors is comparable between women and men. These findings support the use of these therapies in both genders with appropriate indications for use.


Show references

Find this article online at JACC

Share this page with your colleagues and friends: